Parkinsonism Due to the Use of Long-Term High-Dose Valproic Acid in an Elderly Patient with Mania Syndrome: A Case Report and Literature Review

被引:0
作者
Aykut, Demet Saglam [1 ]
Aral, Gizem [1 ]
Tiryaki, Ahmet [2 ]
机构
[1] Karadeniz Tech Univ, Sch Med, Dept Psychiat, Trabzon, Turkey
[2] Aydin Univ, Dept Psychiat, Fac Med, Istanbul, Turkey
来源
PSYCHIATRY AND BEHAVIORAL SCIENCES | 2018年 / 8卷 / 04期
关键词
Valproic acid; parkinsonism; bipolar disorder; mood stabilizer; adverse effect; elderly;
D O I
10.5455/PBS.20180515015339
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Valproic acid (VPA) is used as a mood stabilizer in the treatment of bipolar disorder and is commonly associated with central nervous system side effects. The most common side effect is tremor due to dose, while parkinsonism is a less common side effect. Among psychiatric patients, there are few reports of recurrent parkinsonism attributed to VPA use. However, in the literature, especially among neurological patients, VPA is one of the main important causes of Parkinsonism. Furthermore, the relationship between VPA treatment dose and parkinsonism symptom severity is uncertain. 72-year-old male patient has been followed-up for 30 years with a diagnosis of bipolar disorder and has been receiving a treatment of VPA. After VPA treatment was started, complaints of impairment in speech, walking with small steps, slowed movements, and imbalance which had gradually increased, started within the last 10 years. The patient was admitted to the clinic and assessed for secondary parkinsonism. VPA treatment of the patient was stopped since he was thought to have secondary parkinsonism associated with medication. 4 days after the VPA medication was stopped, it was seen that there was a decrease in bending forward posture and regression in dysphagia and the patient was seen to walk alone without any support. Based on this case, it can be put forward that addressing psychiatry patients who have a long-term use of VPA in terms of parkinsonism symptoms can be significant in terms of not overlooking this side effect that can disrupt the quality of life and also in terms of early diagnosis and treatment.
引用
收藏
页码:199 / 203
页数:5
相关论文
共 25 条
[1]  
Akbostanci M.C., 2000, PARKINSON HAST HAREK, V3, P7
[2]   Reversible parkinsonism and cognitive impairment with chronic valproate use [J].
Armon, C ;
Shin, C ;
Miller, P ;
Carwile, S ;
Brown, E ;
Edinger, JD ;
Paul, RG .
NEUROLOGY, 1996, 47 (03) :626-635
[3]   Clinically silent idiopathic Parkinson's disease unmasked by valproate use: a brief report [J].
Athauda, Dilan ;
Batley, Robert ;
Ellis, Catherine .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2015, 27 (03) :387-390
[4]   Pathophysiology of Parkinson's disease: From clinical neurology to basic neuroscience and back [J].
Bergman, H ;
Deuschl, G .
MOVEMENT DISORDERS, 2002, 17 :S28-S40
[5]   [123I]FP-CIT SPECT (DaTSCAN) may be a useful tool to differentiate between Parkinson's disease and vascular or drug-induced parkinsonisms: a meta-analysis [J].
Brigo, F. ;
Matinella, A. ;
Erro, R. ;
Tinazzi, M. .
EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 (11) :1369-+
[6]   Valproate-Associated Parkinsonism: A Critical Review of the Literature [J].
Brugger, Florian ;
Bhatia, Kailash P. ;
Besag, Frank M. C. .
CNS DRUGS, 2016, 30 (06) :527-540
[7]   Reversible parkinsonism and cognitive decline due to a possible interaction of valproic acid and quetiapine [J].
De Dios, C. ;
Fudio, S. ;
Lorenzo, A. .
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2011, 36 (03) :430-432
[8]   Reversible parkinsonism with normal β-CIT-SPECT in patients exposed to sodium valproate [J].
Easterford, K ;
Clough, P ;
Kellett, M ;
Fallon, K ;
Duncan, S .
NEUROLOGY, 2004, 62 (08) :1435-1437
[9]   MINI-MENTAL STATE - PRACTICAL METHOD FOR GRADING COGNITIVE STATE OF PATIENTS FOR CLINICIAN [J].
FOLSTEIN, MF ;
FOLSTEIN, SE ;
MCHUGH, PR .
JOURNAL OF PSYCHIATRIC RESEARCH, 1975, 12 (03) :189-198
[10]  
Friedman JH, 1992, DRUG INDUCED MOVEMEN, P41